

1
2 **Cross-neutralizing activity against Omicron could be obtained in SARS-CoV-2**
3 **convalescent patients who received two doses of mRNA vaccination**
4
5 Yukiya Kurahashi, MD¹, Koichi Furukawa, MD¹, Silvia Sutandhio, MD¹, Lidya Handayani Tjan,
6 MD, PhD¹, Sachiyo Iwata, MD, PhD², Shigeru Sano, MD, PhD³, Yoshiki Tohma, MD³,
7 Hiroyuki Ohkita, MD⁴, Sachiko Nakamura, MD⁴, Mitsuhiro Nishimura, PhD¹, Jun Arii, DVM,
8 PhD¹, Tatsunori Kiriū, MD, PhD⁵, Masatsugu Yamamoto, MD, PhD⁶, Tatsuya Nagano, MD,
9 PhD⁶, Yoshihiro Nishimura, MD, PhD⁷, Yasuko Mori, MD, PhD^{1*}

10
11 ¹Division of Clinical Virology, Center for Infectious Diseases, Kobe University Graduate School
12 of Medicine, Kobe, Hyogo, Japan

13 ²Division of Cardiovascular Medicine, Hyogo Prefectural Kakogawa Medical Center,
14 Kakogawa, Hyogo, Japan

15 ³Acute Care Medical Center, Hyogo Prefectural Kakogawa Medical Center, Kakogawa, Hyogo,
16 Japan

17 ⁴Division of General Internal Medicine, Hyogo Prefectural Kakogawa Medical Center,
18 Kakogawa, Hyogo, Japan

19 ⁵Division of Respiratory Medicine, Hyogo Prefectural Awaji Medical Center, Sumoto, Hyogo,
20 Japan

21 ⁶Division of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate
22 School of Medicine, Kobe, Hyogo, Japan

23 ⁷Kita-Harima Medical Center, Ono, Hyogo, Japan

24

25 *** Correspondence:**

26 Corresponding Author: Yasuko Mori, MD, PhD^{1*}

27 ymori@med.kobe-u.ac.jp

28

29 **Keywords:** SARS-CoV-2, COVID-19, Omicron, cross-neutralizing antibody, convalescent

30

31 **Running title:** Cross-neutralizing antibody against Omicron

32

33 Words: abstract 85/100, main: 1,974/2000

34

35

36 **Abstract**

37 The SARS-CoV-2 variant Omicron is now under investigation. We evaluated cross-neutralizing
38 activity against Omicron in COVID-19 convalescent patients (n=23) who had received two doses
39 of an mRNA vaccination (BNT162b2 or mRNA-1273). Surprisingly and interestingly, after the
40 second vaccination, the subjects' neutralizing antibody titers including that against Omicron all
41 became seropositive, and significant fold-increases (21.1–52.0) were seen regardless of the
42 subjects' disease severity. Our findings thus demonstrate that at least two doses of mRNA
43 vaccination to SARS-CoV-2 convalescent patients can induce cross-neutralizing activity against
44 Omicron.

45

46 **BACKGROUND**

47 The Coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory
48 syndrome coronavirus 2 (SARS-CoV-2) has been a major public health problem worldwide since
49 November 2019. As of mid-January 2022, more than 310 million individuals worldwide have
50 been infected with SARS-CoV-2, and more than 5.5 million have died [1]. The threat posed by
51 the SARS-CoV-2 variant Omicron (B.1.1.529) is now under intensive investigation. Omicron
52 was first detected in Botswana on 11 November 2021 and in South Africa on 14 November
53 2021, and the rate of increase in the number of individuals infected with this variant has been
54 explosive.

55 In the efforts to control the spread of Omicron, a major challenge has been the low
56 seroconversion rates of cross-neutralizing antibody against Omicron in sera of the individuals
57 who are fully COVID-19-vaccinated [2]. A booster dose of an mRNA vaccine for individuals'
58 acquisition of sufficient cross-neutralizing ability has been recommended by several
59 investigators [3–5] and our research group [6], but as of this writing the data regarding the cross-
60 neutralizing activity against Omicron in COVID-19 convalescent individuals following mRNA
61 vaccination are lacking [5, 7, 8].

62 As elsewhere worldwide, the population of Japan has been attempting to overcome the
63 COVID-19 pandemic. As of mid-January 2022, nearly 1,800,000 Japanese people have been
64 infected with COVID-19, and approx. 18,000 people had died due to this disease [1]. The sixth
65 wave (i.e., surge in new COVID cases) in Japan has been due to the Omicron variant. To control
66 this pandemic in Japan, BNT162b2 vaccination (more commonly known as the Pfizer COVID-
67 19 vaccine) was started in mid-February 2021, and mRNA-1273 vaccination (the Moderna

68 COVID-19 vaccine) was started in mid-May 2021. As of mid-January 2022, 78.9% of Japan's
69 population was fully vaccinated [9].

70 It is important to determine whether the COVID-19 convalescent patients have cross-
71 neutralizing activity against Omicron, because cross-neutralizing activity is the key to protection
72 against reinfection. We thus conducted the present study to evaluate the neutralizing activity
73 against the Delta and Omicron variants in the sera of COVID-19 convalescent patients. We also
74 evaluated the efficacy of two doses of mRNA vaccine by analyzing the neutralizing antibody
75 titer against Omicron in the same individuals.

76

77 **METHODS**

78 **Diagnosis of COVID-19 and definition of severities**

79 A positive SARS-CoV-2 antigen test or positive polymerase chain reaction (PCR)
80 detection of the SARS-CoV-2 genome in nasal, nasopharyngeal, oropharyngeal, or saliva
81 samples were used to confirm the diagnosis of COVID-19. We used the same definitions of
82 severities as in our previous reports [10, 11]; 'Asymptomatic' patients had neither clinical
83 symptoms nor hypoxia. 'Mild' patients had symptoms without evidence of pneumonia or
84 hypoxia. 'Moderate' patients had clinical symptoms of pneumonia with oxygen saturation levels
85 >90% on room air. 'Severe' patients suffered from pneumonia with an oxygen saturation level
86 <90% on room air. 'Critical' patients needed mechanical ventilation. In the present study, we also
87 refer to one group as 'patients without pneumonia'; this group included the patients who did not
88 present with pneumonia (asymptomatic and mild patients). Another group is referred to as
89 'patients with pneumonia', comprised of the patients who presented with pneumonia (moderate,
90 severe and critical patients).

91

92 **Study site and patient recruitment**

93 Serial sera samples of COVID-19 patients have been collected by Hyogo Prefectural
94 Kakogawa Medical Center (Kakogawa, Hyogo, Japan) at various timepoints post-onset: 1–3, 3–
95 6, and 6–9 months post-onset, and approx. 12 months post-onset. In this study, the sera of
96 patients infected between 10 March 2020 and 5 January 2021 are called 'Term 1', those of
97 patients infected between 28 April 2021 and 26 May 2021 are called 'Term 2', and those of
98 patients infected between 10 March 2020 and 5 January 2021 are called 'Term 3' excluding the
99 patients given therapeutic monoclonal antibody drugs.

100 We examined the neutralizing antibody titers among SARS-CoV-2 convalescent patients.
101 Based on the epidemiological data [12], it is likely that the patients in Term 1 were infected with
102 D614G, those in Term 2 were infected with Alpha, and those in Term 3 were infected with Delta.
103 We therefore compared the neutralizing antibody titers against D614G, Delta, Omicron in Term
104 1; we compared the titers against Alpha, Delta, Omicron in Term 2, and we compared those
105 between Delta and Omicron in Term 3.

106

107 **Virus strains**

108 The SARS-CoV-2 Biken-2 (B2) strain and the D614G reference variant (accession no.
109 LC644163) received from BIKEN Innovative Vaccine Research Alliance Laboratories were
110 used. The SARS-CoV-2 variants B.1.1.7 Alpha variant (GISAID ID: EPI_ISL_804007),
111 B.1.167.2 Delta variant (GISAID ID: EPI_ISL_2158617), and B.1.1.529 Omicron variant
112 (GISAID ID: EPI_ISL_7418017) were obtained from the National Institute of Infectious
113 Diseases (NIID), Tokyo.

114

115 **Neutralization assay**

116 The virus neutralization assay against the four SARS-CoV-2 variants D614G, Alpha, Delta,
117 and Omicron was conducted using each authentic virus as described [10, 11] at Biosafety Level
118 3.

119

120 **Statistical analyses**

121 Continuous variables are described using medians and interquartile ranges (IQRs) defined
122 by the 25th and 75th percentiles. Categorical factors are reported as counts and percentages. The
123 neutralizing antibody titers under two were assigned a titer of one for the geometric mean titer
124 (GMT) calculations. The Wilcoxon signed-rank test or Friedman's test and Bonferroni correction
125 were performed to compare the neutralizing antibody titers. The level of statistical significance
126 in all analyses was set at $P < .05$. Statistical analyses were performed using STATA (ver. 14.2).
127 Sample size calculation was not performed.

128

129 **Ethics**

130 Our study was approved by the Ethics Committees of Kobe University Graduate School of
131 Medicine (ID: B200200) and Hyogo Prefectural Kakogawa Medical Center. Written consent or
132 the opt-out consent for our observational study was obtained.

133

134 **RESULTS**

135 **The patients' characteristics**

136 We assessed 40 sera of Term 1 patients, 12 sera of Term 2 patients, and 16 sera of Term 3
137 patients (**Supplementary Table 1 and 2**). We used four groups for the sera based on the four
138 time periods of blood sampling (1–3, 3–6, 6–9, and 12months post-onset). The numbers of
139 patients with pneumonia were Term 1 (n=22), Term 2 (n=12), and Term 3 (n=16). The number
140 of convalescent patients who had received two doses of a vaccine (BNT162b2 or mRNA-1273)
141 was 19 in Term 1 and four in Term 2.

142

143 **Comparison of the neutralizing antibody titers against variants in the patients' sera**

144 We compared the neutralizing antibody titers against SARS-CoV-2 variants from the sera
145 of the COVID-19 convalescent patients. These sera were collected at 1–3 months post-onset
146 (**Figure 1A, 1B, Supplementary Figure 1, and Supplementary Table 3**). The seropositive
147 rates of neutralizing antibody were 97.5% for D614G, 87.5% for Delta, and 37.5% for Omicron
148 (**Figure 1A**). The GMTs of neutralizing antibody were 18.7 against D614G, 7.7 against Delta,
149 and 1.5 against Omicron (**Supplementary Table 3**).

150 The results of our comparison of the neutralizing antibody titers against D614G, Delta, and
151 Omicron in the patients with or without pneumonia in Term 1 are provided in **Supplementary**
152 **Figure 1 and Supplementary Table 3**. Although the GMTs of neutralizing antibody in the
153 patients with pneumonia in Term 1 were higher than those of the patients without pneumonia, the
154 seropositive rate of the Term 1 patients with pneumonia was only 59.1% and the GMT of
155 neutralizing antibody against Omicron was 2.0, the same as the cut-off point.

156 We next compared the neutralizing antibody titers against D614G, Alpha, or Delta with
157 those of Omicron in the patients with pneumonia in Term 1 to Term 3 (**Figure 1B**). We aligned
158 the severity among the patient groups because there were no sera of Term 2 or Term 3 patients

159 without pneumonia. Significant fold-decreases of neutralizing antibody titers against Omicron
160 relative to those against the other variants were observed: 17.6 ($P < .0001$) for Term 1, 12.0 ($P <$
161 $.0001$) for Term 2, and 13.5 ($P < .0001$) for Term 3.

162

163 **Longitudinal analysis of neutralizing antibody titers against D614G, Alpha, Delta, and** 164 **Omicron in patients infected in Term 1 or Term 2 after two vaccine doses**

165 We examined the trends of neutralizing antibody titers in the patients infected during
166 Term 1 after their two doses of vaccination at 1–3, 3–6, 6–9, and 12months post-onset (n=19)
167 (**Figure 2A and Supplementary Table 4**). Two doses of mRNA vaccination were completed
168 before the sera were collected at 12months post-onset. The GMTs of the neutralizing antibody
169 against D614G and Delta tended to decline from 1–3 months post-onset to 6–9 months post-
170 onset. The GMTs of the neutralizing antibody against Omicron were under two among three
171 sampling points. Surprisingly and interestingly, after the two doses of vaccination, all
172 neutralizing antibody titers including that against Omicron became seropositive and showed
173 significant fold-increases (21.1 to 52.0) regardless of the severity of the patients' disease
174 (**Figures 2A and 2C, Supplementary Figure 2A, and 2B**).

175 We then evaluated the trend of neutralizing antibody titers in the patients infected during
176 Term 2 and subsequently vaccinated at 1–3, 3–6, and 6–9 months post-onset (n=4) (**Figures 2B,**
177 **2D, and Supplementary Table 3**). Two doses of the vaccination were completed before the sera
178 were collected at 6–9 months post-onset. The GMTs of the neutralizing antibody against Alpha,
179 Delta, and Omicron tended to decline from 1–3 months post-onset to 3–6 months post-onset.
180 After two doses of the vaccination, a significant fold-increase of the neutralizing antibody titers
181 against Omicron was also observed (**Figures 2B and 2D**), indicating that the neutralizing

182 antibody against Omicron has been boosted by the vaccination; however, the neutralizing
183 antibody titers against Omicron were significantly lower than those against the variants which
184 were suspected to have infected patients (D614G or Alpha) even after vaccination (**Figure 2C,**
185 **2D, Supplementary Figure 2C, and 2D**).

186

187 **DISCUSSION**

188 The results of our analyses revealed that the neutralizing antibody titers against Omicron
189 in the patients infected in Term 1 were remarkably decreased (**Figure 1A, Supplementary**
190 **Figure 1 and Supplementary Table 3**). Notably, the seropositive rate of neutralizing antibody
191 titer against Omicron in the patients without pneumonia in Term 1 was only 11.1%. These data
192 are similar to those of earlier studies [7, 8, 13]. The seropositive rate against Omicron of the
193 patients with pneumonia was higher than that of the patients without pneumonia because a
194 stronger immune response was elicited in the severe COVID-19 patients compared to those with
195 mild disease (**Supplementary Figure 1**) [10].

196 Our findings also demonstrated significant fold-decreases against Omicron relative to
197 D614G ($\times 17.6$), Alpha ($\times 12.0$), and Delta ($\times 13.5$) (**Figure 1B**). Another study showed clear fold-
198 decreases against Omicron compared to Victoria (an early pandemic strain; $\times 16.9$), Alpha
199 ($\times 18.4$), and Delta ($\times 25.9$) [7]. In the present study, the proportion of patients whose condition
200 was considered 'critical' in Term 3 (75%) was much higher than those in Term 1 (9%) and Term
201 2 (58%), this might have contributed to the lesser fold-decrease against Omicron relative to Delta
202 than expected. Our results suggest that patients who have been infected with any SARS-CoV-2
203 variant could be possibly reinfected with Omicron.

204 We also observed that the neutralizing antibody titers against Omicron increased after two
205 doses of mRNA vaccine in Term 1 and Term 2, as in other studies (**Figure 2A, 2B,**
206 **Supplementary Figure 2A, 2B and Supplementary Table 4**) [5,□13]. It was reported that the
207 neutralizing antibody activity against Omicron in convalescent patients who were subsequently
208 vaccinated was around ten times higher than that in fully vaccinated patients without past
209 infection [5,□13]. In the present investigation, the ratios of the neutralizing antibody titer against
210 Omicron relative to the other variants (D614G or Alpha) from vaccinated patients after their
211 recovery (**Figure 2C and 2D**) were almost the same as those against Omicron compared to the
212 D614G in uninfected individuals who received three doses of COVID-19 mRNA vaccine
213 [4,□8,□13]. Although it remains unknown whether one dose is sufficient for convalescent
214 patients with severe symptoms and whether a third dose is necessary for convalescent patients
215 with mild symptoms, our results show that at least two doses of mRNA vaccination to SARS-
216 CoV-2 convalescent patients may induce cross-neutralizing activity against Omicron comparably
217 to three doses of mRNA vaccination to uninfected individuals.

218

219

220 **Footnotes**

221 **Conflict of interest**

222 The authors declare no conflicts of interest associated with this manuscript.

223

224 **Funding/Support**

225 This work was supported by Hyogo Prefectural Government and the Kansai Economic
226 Federation (KANKEIREN). The funders had no role in this study.

227 **Meeting**

228 This study has never been presented anywhere.

229

230 **Corresponding author:**

231 Yasuko Mori, MD, PhD

232 Division of Clinical Virology, Center for Infectious Diseases Kobe University Graduate School

233 of Medicine 7-5-1 Kusunoki-cho, Chuo-ku, Hyogo 650-0017, Japan.

234 Tel: +81-78-382-6272, Fax: +81-78-382-6879

235 E-mail: ymori@med.kobe-u.ac.jp

236

237 **Acknowledgments**

238 We thank Kazuro Sugimura MD, PhD (Superintendent, Hyogo Prefectural Hospital Agency and

239 Professor, Kobe University) for his full support to promote this study. We express our sincere

240 gratitude for cooperation and participation of staffs of Hyogo Prefectural Kakogawa Medical

241 Center. We thank for BIKEN Innovative Vaccine Research Alliance Laboratories providing

242 SARS-CoV-2 B2 strain. We thank the National Institute of Infectious Disease Japan for

243 providing SARS-CoV-2 Alpha, Delta, and Omicron variants. YK obtained Taniguchi Memorial

244 Scholarship program founded by BIKEN Foundation. SS¹ and LT got Japanese Government

245 (Monbukagakusho:MEXT) Scholarships.

246

247 **Author Contributions**

248 All authors contributed to the concept of this article. YK drafted the manuscript; YM provided

249 revisions; YK, JA, MN, and YM analyzed the data; YK, KF, SS¹, and LT did the experiments;

250 YM and YN supervised the experiments; SI, YT, SS³, SN, TK, MY and TN collected the
251 samples; YM conducted the project; All authors approved the final version of the manuscript

252

253 **Figure legends**

254

255 **Figure 1. Comparison of the neutralizing antibody titers against D614G, Alpha, Delta, and**

256 **Omicron from sera of convalescent COVID-19 patients.** *Vertical bar:* The neutralizing

257 antibody titer (log₂ scale). *Horizontal bar:* The SARS-CoV-2 variants. All samples in panels **A**

258 and **B** were collected at 1–3 months post-onset. **A:** The neutralizing antibody titers of the Term 1

259 patients. **B:** The neutralizing antibody titers in the patients with pneumonia infected during

260 Terms 1–3. Wilcoxon signed-rank test or Friedman's test and Bonferroni correction were

261 performed to compare the neutralizing antibody titers. Fold-decreases of neutralizing antibody

262 titer (Delta relative to D614G or Alpha, and Omicron relative to D614G, Alpha, or Delta) are

263 above each graph; seropositive rates are below each graph. *Gray dash* in each graph: The cut-off

264 titer. D614G, Alpha, and Delta are suspected to have infected the individuals in Terms 1, 2, and

265 3, respectively.

266

267 **Figure 2. Comparison of the neutralizing antibody titers against D614G/Alpha, Delta, and**

268 **Omicron in the patients infected during Term 1 or 2 and subsequently vaccinated.** The

269 neutralizing antibody titers against Delta, and Omicron in the patients infected during Term 1

270 and subsequently vaccinated (**A**) and the patients infected during Term 2 and subsequently

271 vaccinated (**B**). **C:** Comparison of the neutralizing antibody titers against D614G, Delta, and

272 Omicron from the same sera as in panel A collected at 12 months post-onset. **D:** Comparison of

273 the neutralizing antibody titers against Alpha, Delta, and Omicron in the same sera as in panel **B**
274 collected at 6–9 months post-onset. *Vertical bar*: The neutralizing antibody titer (log₂ scale).
275 *Horizontal bar*: The timing of sampling (months post-onset) (**A**, **B**) or the SARS-CoV-2 variants
276 used in the virus neutralizing assay (**C**, **D**). *Boxes*: The SARS-CoV-2 variants. Friedman's test
277 and Bonferroni correction were performed to compare the neutralizing antibody titers. Fold-
278 increases of neutralizing antibody titer (12 months post-onset relative to 6–9 months post-onset
279 in **A**, and 6–9 months post-onset relative to 3–6 months post-onset in **B**) are shown above each
280 graph. Fold-decreases of neutralizing antibody titer against Delta and Omicron relative to D614G
281 are indicated in **C**, and those against Delta and Omicron relative to Alpha are indicated in **D**.
282 Seropositive rates are shown below each graph. *Gray dash* in each graph indicates the cut-off
283 titer. One serum at 6–9 months post-onset was missing in the group of patients infected during
284 Term 1 and subsequently vaccinated. An *arrow* in each graph shows the timepoint of the second
285 mRNA vaccination. D614G and Alpha are suspected to have infected the patients during Terms
286 1 and 2, respectively.

287

288 **References**

- 289 1. worldmeter. COVID-19 CORONAVIRUS PANDEMIC. Available at:
290 <https://www.worldometers.info/coronavirus/>. Accessed 9 February 2022.
- 291 2. Dejnirattisai W, Shaw RH, Supasa P, et al. Reduced neutralisation of SARS-CoV-2 omicron
292 B.1.1.529 variant by post-immunisation serum. *Lancet* **2022**; 399:234-6.
- 293 3. Muik A, Lui BG, Wallisch AK, et al. Neutralization of SARS-CoV-2 Omicron by BNT162b2
294 mRNA vaccine-elicited human sera. *Science* **2022**:eabn7591.

- 295 4. Nemet I, Kliker L, Lustig Y, et al. Third BNT162b2 Vaccination Neutralization of SARS-
296 CoV-2 Omicron Infection. *New England Journal of Medicine* **2022**; 386:492-4.
- 297 5. Garcia-Beltran WF, St Denis KJ, Hoelzemer A, et al. mRNA-based COVID-19 vaccine
298 boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant. *Cell* **2022**;
299 185:457-66.e4.
- 300 6. Furukawa K, Tjan LH, Kurahashi Y, et al. Acquired neutralizing breadth against SARS-CoV-
301 2 variants including Omicron after three doses of mRNA COVID-19 vaccination and the vaccine
302 efficacy. *medRxiv* **2022**:2022.01.25.22269735.
- 303 7. Dejnirattisai W, Huo J, Zhou D, et al. SARS-CoV-2 Omicron-B.1.1.529 leads to widespread
304 escape from neutralizing antibody responses. *Cell* **2022**; 185:467-84.e15.
- 305 8. Lusvarghi S, Pollett SD, Neerukonda SN, et al. SARS-CoV-2 Omicron neutralization by
306 therapeutic antibodies, convalescent sera, and post-mRNA vaccine booster. *bioRxiv*
307 **2021**:2021.12.22.473880.
- 308 9. World Health Organization Data. Coronavirus (COVID-19) Vaccinations. Available at:
309 <https://ourworldindata.org/covid-vaccinations>. Accessed 9 February 2022.
- 310 10. Tjan LH, Furukawa K, Nagano T, et al. Early Differences in Cytokine Production by
311 Severity of Coronavirus Disease 2019. *J Infect Dis* **2021**; 223:1145-9.
- 312 11. Furukawa K, Tjan LH, Sutandhio S, et al. Cross-Neutralizing Activity Against SARS-CoV-2
313 Variants in COVID-19 Patients: Comparison of 4 Waves of the Pandemic in Japan. *Open Forum*
314 *Infect Dis* **2021**; 8:ofab430.
- 315 12. Outbreak.info. Japan Variant Report. Available at: [https://outbreak.info/location-](https://outbreak.info/location-reports?loc=JPN)
316 [reports?loc=JPN](https://outbreak.info/location-reports?loc=JPN). Accessed 9 February 2022.

- 317 13. Cameroni E, Bowen JE, Rosen LE, et al. Broadly neutralizing antibodies overcome SARS-
318 CoV-2 Omicron antigenic shift. *Nature* **2021**.

Figure 1






Figure 2




Supplementary Figure 1



Supplementary Figure 1. Comparison of the neutralizing antibody titers against D614G, Delta, and Omicron in the patients infected during Term 1, by severity. *Vertical bar:* The neutralizing antibody titer (log₂ scale). *Horizontal bar:* The SARS-CoV-2 variants. All samples were collected at 1–3 months post-onset. The neutralizing antibody titer in the patients infected during Term 1, those without pneumonia in Term 1, and those with pneumonia in Term 1 are shown. Friedman's test and Bonferroni correction were used to compare the neutralizing antibody titers. Fold-decreases of neutralizing antibody titer (Delta relative to D614G, and Omicron relative to D614G) are shown above each graph. Seropositive rates are shown below each graph. *Gray dash* in each graph indicates the cut-off titer. D614G is thought to have infected the patients during Term 1.

Supplementary Figure 2



Supplementary Figure 2. Comparison of the neutralizing antibody titers against D614G, Delta, and Omicron in the patients infected during Term 1 and subsequently vaccinated, by severity. Comparison of the neutralizing antibody titers against D614G, Delta, and Omicron in the patients without pneumonia in Term 1 and subsequently vaccinated (**A**) and in the patients with pneumonia in Term 1 and subsequently vaccinated (**B**). Comparison of the neutralizing antibody titers against D614G, Delta, and Omicron in the same sera as in panel A collected at 12 months post-onset (**C**). Comparison of the neutralizing antibody titers against Alpha, Delta, and Omicron in the same sera as in panel B collected at 12 months post-onset (**D**). *Vertical bar*: The neutralizing antibody titers (log₂ scale). *Horizontal bar*: The timing of sampling (months post-onset) (**A**, **B**) or SARS-CoV-2 variants used in the virus neutralizing assay (**C**, **D**). *Boxes*: The SARS-CoV-2 variants. Friedman's test and Bonferroni correction were performed to compare the neutralizing antibody titers. Fold-increases of the neutralizing antibody titers (12 months post-onset relative to 6–9 months post-onset in **A**, and 6–9 months post-onset relative to 3–6 months post-onset in **B**) are shown above each graph. Fold-decreases of the neutralizing antibody titers against Delta and Omicron relative to D614G are indicated in **C** and **D**. Seropositive rates are shown below each graph. *Gray dash* in each graph indicates the cut-off titer. One serum at 6–9 months post-onset was missing in the group of patients infected during Term 1 and subsequently vaccinated. An *arrow* in each graph indicates the timepoint of the second mRNA vaccination. D614G is thought to have infected the patients during Term 1.

Supplementary Table 1

Characteristics of convalescent patients

Convalescent patients infected with SARS-CoV-2		Term 1 (n=40)	Term 2 (n=12)	Term 3 (n=16)	
Age ^a (median with IQR)		56 (48.5-61.5)	67 (55.5-72.5)	58 (52.5-59)	
Sex-Female (n with %)		21 (52.5%)	3 (25%)	4 (25%)	
Sampling time of sera	1-3 months	40	12	16	
	3-6 months	40	4	-	
Post month onset (n)	6-9 months	35	4	-	
	12 months	19	-	-	
Severity (n)	Pneumonia(-)	Asymptomatic	3	0	0
		Mild	15	0	0
	Moderate	5	0	0	
	Pneumonia(+)	Severe	15	5	4
		Critical	2	7	12
Completed two dose of mRNA vaccine		19	4	0	

a: Age are counted when patients were enrolled in our study.

Supplementary Table 2

Median days post onset of sampling sera for SARS-CoV-2 convalescent patients

Sera	Sampling time (month post onset)	Median days with IQR	
Term 1	1-3m (n=40)	46.5	(42.5-54)
	3-6m (n=40)	116.5	(109-132)
	6-9m (n=35)	202	(197-215)
	12m (n=19)	379	(368-395)
Term 2	1-3m (n=12)	41	(34.5-48)
	3-6m (n=4)	108.5	(100.5-119)
	6-9m (n=4)	199.5	(192.5-209)
Term 3	1-3m (n=21)	43	(39-51)

Supplementary Table 3

Geometric mean titers (GMTs) of neutralizing antibody in sera of SARS-CoV-2 convalescent patients at 1-3 months onset

Sera	Variant	GMT of neutralizing antibody ^a	
Term 1 (n=40)	D614G	18.7	(13.1-26.6)
	Delta	7.7	(5.4 -11.0)
	Omicron	1.5	(1.2 - 1.9)
Term 1 without pneumonia (n=18)	D614G	8.6	(5.3 -14.0)
	Delta	3.4	(2.2 - 5.4)
	Omicron	1.1	(1.0 -1.2)
Term 1 with pneumonia (n=22)	D614G	35.2	(25.2-49.0)
	Delta	15.0	(10.7-21.1)
	Omicron	2.0	(1.5 -2.7)
Term 2 with pneumonia (n=12)	Alpha	60.4	(40.6-89.8)
	Delta	18.0	(13.1-24.6)
	Omicron	5.0	(2.3-11.3)
Term 3 with pneumonia (n=16)	Delta	133.7	(94.9-188.4)
	Omicron	9.9	(5.3 -18.6)

a: Neutralizing antibody titers under two were assigned a titer of one for geometric mean titer (GMT) calculations. GMTs were shown with 95% CI.

Supplementary Table 4

**Geometric mean titers (GMTs) of neutralizing antibody
in sera of SARS-CoV-2 convalescent, subsequently vaccinated patients**

Sera	Virus	Month post onset	GMT of neutralizing antibody ^a
Patients infected during Term 1, subsequently vaccinated (n=19)	D614G	1-3m	21.4 (13.0-35.4)
		3-6m	16.6 (9.8-28.1)
		6-9m	11.8 (7.3-18.9)
		12m	368.7 (215.2-631.6)
	Delta	1-3m	10.3 (5.9-18.1)
		3-6m	6.0 (3.9-9.1)
		6-9m	4.7 (2.7-8.1)
		12m	171.4 (103.7-283.1)
	Omicron	1-3m	1.5 (1.1-2.1)
		3-6m	1.7 (1.2-2.4)
		6-9m	1.5 (1.1-2.0)
		12m	51.4 (25.6-103.1)
Patients infected during Term 1, subsequently vaccinated without pneumonia (n=8)	D614G	1-3m	11.3 (4.7-27.2)
		3-6m	8.0 (4.0-16.0)
		6-9m	5.7 (3.3-9.7)
		12m	279.2 (79.5-980.1)
	Delta	1-3m	4.8 (2.0-11.3)
		3-6m	3.4 (1.6-7.1)
		6-9m	2.4 (1.2-4.7)
		12m	117.4 (41.2-334.6)
	Omicron	1-3m	1.1 (0.9-1.3)
		3-6m	1.2 (0.9-1.6)
		6-9m	1.1 (0.9-1.3)
		12m	26.9 (7.0-102.9)
Patients infected during Term 1, subsequently vaccinated with pneumonia (n=11)	D614G	1-3m	34.1 (20.1-57.8)
		3-6m	28.2 (14.7-54.2)
		6-9m	21.1 (12.4-36.0)
		12m	451.4 (273.1-745.9)
	Delta	1-3m	18.1 (9.8-33.7)
		3-6m	9.1 (6.0-13.6)
		6-9m	8.0 (3.8-16.8)
		12m	225.7 (131.0-388.7)
	Omicron	1-3m	2.0 (1.2-3.3)

~~All rights reserved. No reuse allowed without permission.~~

		3-6m	2.2	(1.4- 3.7)
		6-9m	1.9	(1.1- 3.2)
		12m	82.3	(37.5-180.9)
Patients infected during Term 2, subsequently vaccinated (n=4)	Alpha	1-3m	38.1	(21.9-66.1)
		3-6m	22.6	(12.0-42.8)
		6-9m	362.0	(120.1-1090.8)
	Delta	1-3m	13.5	(7.8-23.4)
		3-6m	9.5	(5.5-16.5)
		6-9m	152.2	(52.9-437.6)
	Omicron	1-3m	4.0	(0.7-24.2)
		3-6m	2.8	(1.5- 5.3)
		6-9m	90.5	(21.8-375.9)

a: Neutralizing antibody titers under two are assigned a titer of one for geometric mean titer (GMT) calculations. GMTs were shown with 95% CI.